+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Candidiasis Infection Drug Pipeline Study, H2 2018- Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs for Candidiasis

  • ID: 4629653
  • Report
  • September 2018
  • Region: Global
  • 65 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Acea Biotech Inc
  • Cellix Bio Pvt Ltd
  • Dermala Inc
  • iCo Therapeutics Inc.
  • Nosopharm SAS
  • Profem GmbH
  • MORE
Candidiasis Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Candidiasis Infection pipeline products.

Report Description

The Candidiasis Infection pipeline guide presents complete overview of drugs currently being developed for Candidiasis Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Candidiasis Infection pipeline candidate.

Research and Development progress along with latest news related to each of the Candidiasis Infection pipeline candidates is included.

Major companies participating in therapeutic development of Candidiasis Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Candidiasis Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Candidiasis Infection clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Candidiasis Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

Scope of Candidiasis Infection pipeline report includes
  • Panorama of Candidiasis Infection pipeline markets including statistics on therapeutic drugs and companies involved
  • Candidiasis Infection Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
  • Candidiasis Infection pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
  • Overview of companies participating in Candidiasis Infection pipeline with short introduction to their businesses and pipeline projects
  • For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
  • Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Candidiasis Infection pipeline therapeutics
Reasons to Buy
  • Get clear understanding of the entire Candidiasis Infection pipeline, with details on active projects
  • Get in detail information of each product with updated information on each project along with key milestones
  • Know the list of companies participating in global Candidiasis Infection pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Acea Biotech Inc
  • Cellix Bio Pvt Ltd
  • Dermala Inc
  • iCo Therapeutics Inc.
  • Nosopharm SAS
  • Profem GmbH
  • MORE
I. Key Findings

1. Companies Investing in Candidiasis Infection Pipeline include-
Number of Companies with Candidiasis Infection projects in pre-clinical Development-
Number of Companies with Candidiasis Infection projects in Clinical Development-
Candidiasis Infection Pipeline Companies based in Americas
Candidiasis Infection Pipeline Companies based in Europe
Candidiasis Infection Pipeline Companies based in Asia Pacific
Candidiasis Infection Pipeline Companies based in Rest of the World

2. Pipeline Candidates include-
Candidiasis Infection Pipeline Agents in pre- clinical/ Discovery stage of Development
Candidiasis Infection Pipeline Agents in Clinical Development stage
Candidiasis Infection Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Candidiasis Infection Pipeline agents

II. Insights into Candidiasis Infection Pipeline -

1. Disease Overview
Introduction to Candidiasis Infection
Symptoms and Causes of Candidiasis Infection
Treatment or Prevention Options for Candidiasis Infection
Other Details
2. Phase wise Pipeline Compounds
Candidiasis Infection Pipeline- Pre- Clinical/ Discovery stage Drugs
Candidiasis Infection Pipeline- Phase 1 stage Drugs
Candidiasis Infection Pipeline- Phase 2 stage Drugs
Candidiasis Infection Pipeline- Phase 3 stage Drugs
Candidiasis Infection Pipeline- Pre-Registration stage Drugs
3. Company wise Candidiasis Infection Pipeline Compounds
4. Candidiasis Infection Pipeline by Mechanism of Action

III. Candidiasis Infection Pipeline Compound Details
  • Amphotericin B
  • APX-001
  • APX-001A
  • AC17
  • Isavuconazonium
  • Anti fungal drug
  • candidiasis therapeutics
  • BSG005
  • CLX-1593
  • JSM-11
  • Rezafungin
  • P-113 for Oral Candidiasis
  • microbiome(Dermala)
  • Arasertaconazole
  • Drug for Candidiasis
  • pHyph
  • P113
  • ABV3
  • iCo-009
  • MAT2203
  • TP enzyme for Candidiasis
  • NM147
  • NOSO-F2
  • NP339
  • NDV-3
  • NDV-3A
  • Orynotides
  • ProF-001
  • Occidiofungin
  • SCY-078
  • SLP0901
  • Voriconazole sodium phosphate
  • Myc-102
  • TOL-463
  • VT-1161
  • VIS-FNG
  • candidiasis vaccine
Drug Details

1. Snapshot-
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/ License Partner
Orphan Drug / Fast Track/ Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details

IV. Candidiasis Infection Pipeline Company Briefs
  • Acea Biotech Inc
  • Amplyx Pharmaceuticals Inc
  • Amplyx Pharmaceuticals Inc
  • Arietis Corp
  • Basilea Pharmaceutica
  • Biomar Microbial Technologies
  • Bionex Pharmaceuticals LLC
  • Biosergen AS
  • Cellix Bio Pvt Ltd
  • Chelation Partners Inc
  • Cidara Therapeutics Inc
  • Demegen
  • Dermala Inc
  • Ferrer Internacional, SA
  • Fox Chase Chemical Diversity Center Inc
  • Gedea Biotech AB
  • General Biologicals Corp
  • Hennepin Life Sciences LLC
  • iCo Therapeutics Inc.
  • Matinas BioPharma
  • Metabolab Inc
  • Nanomerics Ltd
  • Nosopharm SAS
  • Novabiotics Ltd
  • NovaDigm Therapeutics Inc
  • NovaDigm Therapeutics Inc
  • Oryn Therapeutics
  • Profem GmbH
  • Sano Chemicals Inc
  • Scynexis Inc
  • Sealife PHARMA GMBH
  • Shaanxi Synthetic Pharmaceutical Co Ltd
  • TGV Laboratories Inc
  • Toltec Pharmaceuticals LLC
  • Viamet Pharmaceuticals Inc
  • Visterra Inc
  • Wellstat Vaccines LLC
V. Latest News and Developments in Global Candidiasis Infection Pipeline Market

VI. Appendix
1. Publisher's Expertise
2. Research Methodology
3. Contact Information

Some of the sections depicted above may be removed or modified on the basis of information availability"
Note: Product cover images may vary from those shown
3 of 3
  • Acea Biotech Inc
  • Amplyx Pharmaceuticals Inc
  • Arietis Corp
  • Basilea Pharmaceutica
  • Biomar Microbial Technologies
  • Bionex Pharmaceuticals LLC
  • Biosergen AS
  • Cellix Bio Pvt Ltd
  • Chelation Partners Inc
  • Cidara Therapeutics Inc
  • Demegen
  • Dermala Inc
  • Ferrer Internacional, SA
  • Fox Chase Chemical Diversity Center Inc
  • Gedea Biotech AB
  • General Biologicals Corp
  • Hennepin Life Sciences LLC
  • iCo Therapeutics Inc.
  • Matinas BioPharma
  • Metabolab Inc
  • Nanomerics Ltd
  • Nosopharm SAS
  • Novabiotics Ltd
  • NovaDigm Therapeutics Inc
  • Oryn Therapeutics
  • Profem GmbH
  • Sano Chemicals Inc
  • Scynexis Inc
  • Sealife PHARMA GMBH
  • Shaanxi Synthetic Pharmaceutical Co Ltd
  • TGV Laboratories Inc
  • Toltec Pharmaceuticals LLC
  • Viamet Pharmaceuticals Inc
  • Visterra Inc
  • Wellstat Vaccines LLC
Note: Product cover images may vary from those shown
Adroll
adroll